Mainstay Capital Management’s Gilead Sciences GILD Stock Holding History

Mainstay Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-17,017	Closed	-$991K	–	126
2020 Q4	$991K	Sell	17,017 -2,598	-13%	-$157K	0.29%	57
2020 Q3	$1.24M	Sell	19,615 -2,015	-9%	-$140K	0.32%	46
2020 Q2	$1.66M	Buy	+21,630	New	+$1.66M	0.48%	29
2019 Q4	–	Sell	-19,197	Closed	-$1.22M	–	108
2019 Q3	$1.22M	Buy	19,197 +1,305	+7%	+$85.3K	0.67%	46
2019 Q2	$1.21M	Buy	17,892 +3,375	+23%	+$222K	0.63%	46
2019 Q1	$943K	Sell	14,517 -1,875	-11%	-$125K	0.72%	48
2018 Q4	$1.02M	Buy	16,392 +10,635	+185%	+$743K	0.74%	42
2018 Q3	$444K	Sell	5,757 -7,195	-56%	-$543K	0.28%	71
2018 Q2	$918K	Buy	12,952 +280	+2%	+$19.8K	0.72%	41
2018 Q1	$955K	Buy	12,672 +2,430	+24%	+$193K	0.73%	39
2017 Q4	$734K	Buy	+10,242	New	+$778K	0.61%	47

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Mainstay Capital Management's GILD Position: Q1 2021 in Review

Mainstay Capital Management sold out of Gilead Sciences (GILD) in Q1 2021, closing a stake of 17,017 shares — an estimated $991K sold.

Mainstay Capital Management first reported a position in GILD in Q4 2017 and held it in 11 quarters. The position peaked at $1.66M in Q2 2020. 1,568 funds tracked by Wall St. Rank hold GILD as of Q1 2021.

Mainstay Capital Management reported no remaining Gilead Sciences position as of Q1 2021 after selling out during the quarter.
Mainstay Capital Management sold 17,017 Gilead Sciences shares in Q1 2021, an estimated $991K.
Mainstay Capital Management first reported a position in Gilead Sciences in Q4 2017 and held it in 11 quarters.
Mainstay Capital Management's Gilead Sciences position peaked at $1.66M in Q2 2020.
1,568 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2021.

Based on Mainstay Capital Management's 13F filing for Q1 2021, filed 13 May 2021.